Get App
Download App Scanner
Scan to Download
Advertisement

Cipla Target Price Cut Post Q1, Yet Remains A Top Pick — Here's Why Nirmal Bang Remains Bullish

Nirmal Bang expects Cipla to deliver a 10% revenue CAGR over FY26-FY28E, underpinned by a stronger US pipeline, resilient domestic franchise, and healthy international execution.

Cipla Target Price Cut Post Q1, Yet Remains A Top Pick — Here's Why Nirmal Bang Remains Bullish
Nirmal Bang continue to view Cipla as one of its preferred ideas in the Indian pharma sector, given its attractive combination of earnings visibility, improving return profile, and optionality from future launches.
(Photo: NDTV Profit/ AI generated image)
STOCKS IN THIS STORY
Cipla Ltd.
--

NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Nirmal Bang Report

Domestic brokerage firm Nirmal Bang has maintained its Buy rating on Cipla Ltd. with a revised target price of Rs 1,615 from Rs 1,883, based on 26 times FY28E earnings per share of Rs 62.1.

While the brokerage has moderated its earnings estimates to reflect a slower near-term recovery in the US business, its medium-term investment thesis remains intact.

Nirmal Bang believes Cipla is entering the next phase of growth, underpinned by sustained double-digit momentum in the India business, a differentiated and increasingly visible respiratory pipeline in the US, and an improving mix of complex products that should support margin expansion as launch-related investments normalise.

The company's strong execution track record, industry-leading balance sheet with ~Rs 9,500 crore net cash, and ample optionality for value-accretive capital allocation further strengthen its long-term growth profile.

The brokerage continue to view Cipla as one of our preferred ideas in the Indian pharmaceutical sector, given its attractive combination of earnings visibility, improving return profile, and optionality from future launches.

Click on the attachment to read the full report:

Nirmal Bang Cipla Q1 Review.pdf
VIEW DOCUMENT

ALSO READ: IndiGo Q1 Review: Motilal Oswal Sees 31% Upside Despite Margin Pressure, Fuel Cost Headwinds — Check Target Price

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.

To continue reading this story
You must be an existing Premium User

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search
Add NDTV Profit As Google Preferred Source
Loading PDF...
Listen to the latest songs, only on JioSaavn.com